% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Jost:902002,
author = {Jost, Stefanie T. and Ray Chaudhuri, K. and Ashkan,
Keyoumars and Loehrer, Philipp A. and Silverdale, Monty and
Rizos, Alexandra and Evans, Julian and Petry-Schmelzer, Jan
Niklas and Barbe, Michael T. and Sauerbier, Anna and Fink,
Gereon R. and Visser-Vandewalle, Veerle and Antonini, Angelo
and Martinez-Martin, Pablo and Timmermann, Lars and Dafsari,
Haidar S.},
title = {{S}ubthalamic {S}timulation {I}mproves {Q}uality of {S}leep
in {P}arkinson {D}isease: {A} 36-{M}onth {C}ontrolled
{S}tudy},
journal = {Journal of Parkinson's Disease},
volume = {11},
number = {1},
issn = {1877-718X},
address = {Amsterdam},
publisher = {IOS Press},
reportid = {FZJ-2021-03965},
pages = {323 - 335},
year = {2021},
abstract = {Background:Sleep disturbances and neuropsychiatric symptoms
are some of the most common nonmotor symptoms in
Parkinson’s disease (PD). The effect of subthalamic
stimulation (STN-DBS) on these symptoms beyond a short-term
follow-up is unclear.Objective:To examine 36-month effects
of bilateral STN-DBS on quality of sleep, depression,
anxiety, and quality of life (QoL) compared to
standard-of-care medical therapy (MED) in PD.Methods:In this
prospective, controlled, observational, propensity score
matched, international multicenter study, we assessed sleep
disturbances using the PDSleep Scale-1 (PDSS), QoL employing
the PDQuestionnaire-8 (PDQ-8), motor disorder with the
Scales for Outcomes in PD (SCOPA), anxiety and depression
with the Hospital Anxiety and Depression Scale (HADS), and
dopaminergic medication requirements (LEDD). Within-group
longitudinal outcome changes were tested using Wilcoxon
signed-rank and between-group longitudinal differences of
change scores with Mann-Whitney U tests. Spearman
correlations analyzed the relationships of outcome parameter
changes at follow-up.Results:Propensity score matching
applied on 159 patients (STN-DBS n = 75, MED n = 84)
resulted in 40 patients in each treatment group. At 36-month
follow-up, STN-DBS led to significantly better PDSS and
PDQ-8 change scores, which were significantly correlated. We
observed no significant effects for HADS and no significant
correlations between change scores in PDSS, HADS, and
LEDD.Conclusions:We report Class IIb evidence of beneficial
effects of STN-DBS on quality of sleep at 36-month
follow-up, which were associated with QoL improvement
independent of depression and dopaminergic medication. Our
study highlights the importance of sleep for assessments of
DBS outcomes.},
cin = {INM-3},
ddc = {610},
cid = {I:(DE-Juel1)INM-3-20090406},
pnm = {5251 - Multilevel Brain Organization and Variability
(POF4-525)},
pid = {G:(DE-HGF)POF4-5251},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:33074192},
UT = {WOS:000618063800028},
doi = {10.3233/JPD-202278},
url = {https://juser.fz-juelich.de/record/902002},
}